Farmaceutisch Tijdschrift voor België – 99ste jaargang nr. 1 - maart 2019 15
Referenties
1 Zuberbier et al. Economic burden
of inadequate management of
allergic diseases in the European
Union: a GA(2) LEN review. Allergy.
2014;69(10):1275-9
2 Mehuys E. et al. Self-medication
in persistent rhinitis: overuse of
decongestants in half of the patients.
J Allergy Clin Immunol Pract.
2014;2(3):313-9
3 Tan et al. The Burden of Rhinitis
and the Impact of Medication
Management within the Community
Pharmacy Setting. J Allergy Clin
Immunol Pract. 2018;6(5):1717-1725
4 Cruz A.A et al. Common
characteristics of upper and lower
airways in rhinitis and asthma: ARIA
update, in collaboration with GA(2)
LEN. Allergy 2007; 62: 1–41
5 Cornwell S., Foulon V.
Zelfzorgadvies in de apotheek-deel
2. ACCO Uitgeverij, 16 oktober 2018
6 NHG-Standaard Allergische en
niet-allergische rinitis (tweede
herziening 2018). Beschikbaar op:
https://www.nhg.org/standaarden/
samenvatting/allergische-en-nietallergische
rhinitis
7 Bousquet J et al. aria workshop
group, world health organization.
Allergic rhinitis and its impact on
asthma. Allergy 2008;63 (suppl 86)
8 Greiner A.N. et al. Allergic Rhinitis.
Lancet. 2011;378(9809):2112-22
9 Juel-Berg N. et al. Intranasal
corticosteroids compared with oral
antihistamines in allergic rhinitis:
A systematic review and metaanalysis.
Am J Rhinol Allergy.
2017;31(1):19-28
10 Carr W. et al. A novel intranasal
therapy of azelastine with
fluticasone for the treatment of
allergic rhinitis. J Allergy Clin
Immunol. 2012;129(5):1282-1289
11 Bousquet J. et al. Advances in
pharmacotherapy for the treatment
of allergic rhinitis; MP29-02 (a
novel formulation of azelastine
hydrochloride and fluticasone
propionate in an advanced delivery
system) fills the gaps. Expert Opin
Pharmacother. 2015;16(6):913-28
12 Azélastine + fluticasone - Dymista°.
Rhinite allergique : en rester à une
monothérapie par voie nasale Rev.
Prescrire 2015;35(380):412
13 Han D. et al. A multicenter
randomized double-blind 2-week
comparison study of azelastine nasal
spray 0.1% versus levocabastine
nasal spray 0.05% in patients with
moderate-to-severe allergic rhinitis.
ORL J Otorhinolaryngol Relat Spec.
2011;73(5):260-5.
14 Décongestionnants
vasoconstricteurs et risques
cardiovasculaires: compléter les
RCP ne suffit pas. Rev. Prescrire
2011;31:660.
15 FAGG. Aanbevelingen voor een goed
gebruik van nasale vasoconstrictoren
bij verkoudheid. 08/03/2017.
Beschikbaar op: https://www.fagg.
be/nl/news/aanbevelingen_voor_
een_goed_gebruik_van_nasale_
vasoconstrictoren_bij_verkoudheid
16 Hermelingmeier K.E. et al. Nasal
irrigation as an adjunctive treatment
in allergic rhinitis: A systematic
review and meta-analysis. Am J
Rhinol Allergy. 2012;26(5):e119–
e125. Beschikbaar op: https://www.
ncbi.nlm.nih.gov/pmc/articles/
PMC3904042/pdf/zrie119.pdf
17 BCFI. Transparantiefiche –
Hooikoorts. 2008. Beschikbaar op:
http://www.bcfi.be/tf/NL/TN_HK.pdf
18 CYBELE geneesmiddelen voor
en tijdens zwangerschap en
borstvoeding. 2019. Beschikbaar op:
https://www.cybele.be/
19 Church D.S. et al. Allergic rhinitis:
impact, diagnosis, treatment and
management. Clinical pharmacist
2016;8(8):249-255
20 FAGG. Voorwaarden voor de OTCswitch
van nasale corticosteroïden.
Beschikbaar op: https://www.
fagg-afmps.be/sites/default/files/
voorwaarden_voor_otc-switch_
nasale_corticosteroiden_-_
final_17_03_01.pdf
21 UZLeuven. Allergie, informatie voor
patiënten. Beschikbaar op: https://
www.uzleuven.be/sites/default/files/
brochures/Allergie.pdf
22 NHS choices. Hay fever. Beschikbaar
op: https://www.nhs.uk/conditions/
hay-fever/
23 Bousquet J. et al. MACVIA-ARIA
Sentinel NetworK for allergic rhinitis
(MASK-rhinitis): the new generation
guideline implementation. Allergy
2015;70(11):1372-1392. Beschikbaar
op: https://onlinelibrary.wiley.com/
doi/full/10.1111/all.12686
24 Portnoy J. et al. Environmental
assessment and exposure control
of dust mites: a practice parameter.
Ann Allergy Asthma immunol
2013;111:465-507. Beschikbaar op:
https://www.annallergy.org/article/
S1081-1206(13)00718-7/fulltext
25 Nurmatov U. et al. House dust mite
avoidance measures for perennial
allergic rhinitis: an updated
Cochrane systematic review. Allergy
2012;67(2):158-65
26 Arroyave WD. et al. Impermeable
dust mite covers in the primary
and tertiary prevention of allergic
disease: a meta-analysis. Ann Allergy
Asthma Immunol. 2014;112(3):237-48
27 https://airallergy.sciensano.be/nl
28 Bousquet J. et al. MACVIA Clinical
Decision Algorithm in Allergic
Rhinitis in adolescents and adults.
Journal of Allergy and Clinical
Immunology 2016;138(2):367-
374. Beschikbaar op: https://
www.jacionline.org/article/
S0091-6749(16)30148-8/fulltext
29 Bousquet J. et al. MASK 2017:
ARIA digitally-enabled, integrated,
person-centred care for rhinitis
and asthma multimorbidity using
real-world-evidence. Clinical and
Translational Allergy2018;8:45.
Beschikbaar op: https://ctajournal.
biomedcentral.com/articles/10.1186/
s13601-018-0227-6
Praktijk
/
/www.fagg
/www
/www
/
/TN_HK.pdf
/
/
/
/
/
/nl
/
/ctajournal
/